| Keywords: |
treatment outcome; disease-free survival; genetics; mutation; mortality; patient selection; antineoplastic agents; disease free survival; antineoplastic agent; metabolism; protein kinase inhibitor; epidermal growth factor receptor; receptor, epidermal growth factor; enzymology; pathology; time; time factors; rash; protein kinase inhibitors; colorectal neoplasms; drug cost; economics; drug costs; protein p21; proto-oncogene proteins p21(ras); cost-benefit analysis; cost benefit analysis; egfr protein, human; kras protein, human; exanthema; molecularly targeted therapy; molecular targeted therapy; humans; human; antagonists and inhibitors; chemically induced
|
